Catalyst

Slingshot members are tracking this event:

OncoSec Medical's (ONCS) Interim Results from Phase 2 Study of ImmunoPulse IL-12 and Merck's (MRK) KEYTRUDA in Unresectable Metastatic Melanoma to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ONCS

100%
MRK

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Immunopulse Il-12, Keytruda, Unresectable Metastatic Melanoma, Society For Immunotherapy Of Cancer